^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Pancreatic Cancer
    Drug:SCH772984 (ERK inhibitor) +
    AZD8186 (PI3Kβ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Cell
    Title:

    Long-term ERK Inhibition in KRAS-mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression

    Excerpt:
    SCH772984-sensitive PDX cell lines also exhibited synergy when exposed to the combination of SCH772984 and AZD8186...Together, our data suggest ERK and PI3K inhibitors as a potential clinically relevant combination therapy in KRAS-mutant PDAC.
    DOI:
    10.1016/j.ccell.2015.11.011